Opioid agonist therapy cost-effective for preventing HIV | Compounding pharmacies could help alleviate drug shortages | Pfizer's anemia biosimilar gets FDA panel recommendation
May 26, 2017
Specialty Pharmacy SmartBrief
News for the specialty pharmacy industry
SIGN UP ⋅   FORWARD
Leading News
Opioid agonist therapy cost-effective for preventing HIV
Researchers found that opioid agonist therapy was the most cost-effective method for HIV prevention among injection drug users, according to a study in PLOS Medicine. It was found to be more cost-effective than needle exchanges and test-and-treat programs.
Specialty Pharmacy Times (5/25) 
LinkedIn Twitter Facebook Google+ Email
Specialty Pharmacy Update
Compounding pharmacies could help alleviate drug shortages
Compounding pharmacies could help ease the shortage of high-demand drugs such as sodium bicarbonate, said International Academy of Compounding Pharmacists President Baylor Rice. IACP is communicating to Congress its stance that the FDA should revise its December 2016 guidance blocking 503A pharmacies from office-use compounding.
Drug Topics (5/25) 
LinkedIn Twitter Facebook Google+ Email
Legislation & Regulation
Pfizer's anemia biosimilar gets FDA panel recommendation
Pfizer's biosimilar to Amgen's Epogen, or epoetin alfa, has been recommended by the FDA's Oncologic Drugs Advisory Committee for all indications. Pfizer has an agreement with Vifor Pharma for the marketing of the drug.
Seeking Alpha (free registration) (5/25) 
LinkedIn Twitter Facebook Google+ Email
Trovagene reports on results for Phase I study for its blood cancer candidate
Results from an early-stage study to test the safety of Trovagene's blood cancer candidate PCM-075 showed reversible toxicities including thrombocytopenia and neutropenia. A Phase I/II study is also being planned to test the drug in patients with acute myeloid leukemia.
Seeking Alpha (free registration) (5/25) 
LinkedIn Twitter Facebook Google+ Email
Insurance lobby group calls for immediate action on CSR subsidies
AHIP calls for immediate action on CSR subsidies.
(Win McNamee/Getty Images)
America's Health Insurance Plans sent a letter to Senate Finance Committee Chairman Orrin Hatch, R-Utah, reinforcing calls for swift action to ensure continued funding of cost-sharing reduction payments and emphasizing the need for clarity on individual market provisions to keep insurers in markets and premiums down. AHIP President and CEO Marilyn Tavenner also called on Senate Republicans to guard against disruptions in Medicaid funding and retain protections for those with pre-existing conditions "including guaranteed issue, community rating, and barring pre-existing condition exclusions."
Modern Healthcare (tiered subscription model) (5/25),  The Hill (5/25) 
LinkedIn Twitter Facebook Google+ Email
 
Drafting of Senate health care bill to begin over recess
Sens. Ron Johnson, R-Wis., Bill Cassidy, R-La., and John Cornyn, R-Texas, said Republican leadership staff and committee staff will be drafting health care legislation while the Senate is on break, and Johnson said a discussion draft should be ready for distribution among Republican senators after the recess. The staff will only be working on base language as senators have yet to reach final agreement, Cornyn noted.
The Hill (5/25) 
LinkedIn Twitter Facebook Google+ Email
What the new FDA chief can do about drug prices
Specialty-drug makers that have relied on high prices could be in for trouble if FDA Commissioner Scott Gottlieb implements policies to reduce drug prices by increasing competition in the marketplace, Max Nisen writes. The FDA could relax restrictions on communications between drugmakers and payers before drugs are approved, be more flexible about drug approvals, approve generic drugs faster and prioritize approval of biosimilars.
Bloomberg (5/24) 
LinkedIn Twitter Facebook Google+ Email
Clinical & Research News
Anika announces completion date of supplemental trial of knee pain drug
Anika Therapeutics said it anticipates completion of its supplemental late-stage trial of Cingal for osteoarthritis-related knee pain in 2018 and FDA approval in 2019. The company has enrolled its first patient in the trial.
Reuters (5/25) 
LinkedIn Twitter Facebook Google+ Email
Cancer Moonshot makes progress, but barriers remain
The cancer research community "galvanized around" former Vice President Joe Biden's National Cancer Moonshot initiative, including basic researchers, the private sector and advocates, says Dinah Singer, acting deputy director of the National Cancer Institute. Since the program's inception, three large data-sharing initiatives have been launched and a new platform was developed to facilitate clinical trial enrollment, but budget cuts, continuing EHR interoperability challenges and soaring drug prices threaten progress.
Healio (free registration)/HemOnc Today (5/25) 
LinkedIn Twitter Facebook Google+ Email
Trends & Technology
Harpoon Therapeutics gains $45M to develop immuno-oncology platform
A Series B financing round raised $45 million for Harpoon Therapeutics. The company will use the funds to develop its antibody-based trispecific T-cell-activating construct platform and to launch clinical studies for its two lead candidates based on the technology.
Genetic Engineering & Biotechnology News (5/25) 
LinkedIn Twitter Facebook Google+ Email
NASP News
SmartBrief will not publish Monday
In observance of Memorial Day in the US, SmartBrief will not publish Monday. Publication will resume Tuesday.
LinkedIn Twitter Facebook Google+ Email
Learn more about NASP:
Home page | Membership | News | Annual Meeting
  
  
The real fountain of youth is hidden in the imagination you draw upon to face everyday challenges.
Sophia Loren,
actress
LinkedIn Twitter Facebook Google+ Email
  
  
Sign Up
SmartBrief offers 200+ newsletters
Advertise
Learn more about the SmartBrief audience
Subscriber Tools:
Contact Us:
Advertising  -  Wynn Hansen
P: 202.470.1149
Partner Relations Manager  -  Lauren Barr
Editor  -  Tom Parks
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2017 SmartBrief, Inc.®
Privacy policy |  Legal Information